In the Network Genomic Medicine (NGM) lung cancer hospitals and specialist practices across Germany work together to provide all lung cancer patients with a comprehensive molecular analysis of their tumor. The aim is to detect so-called driver mutations in your tumor tissue, which can be treated with targeted drugs.
For this purpose your physician requests the molecular diagnosis in the network’s headquarters at the University Hospital of Cologne. Once we have received the tumor tissue, it is examined for all molecular changes that might have therapeutic relevance for you, now or in the future. Within the network, we also try to offer our patients with a detected mutation, a suitable clinical trial using a new drug. Your doctor will inform you on changes found in your body, as well as on possible personalized therapeutic approaches.